Consensus on improving the care integrated of patients with acute heart failure;Consenso para la mejora de la atención integral a los pacientes con insuficiencia cardiaca aguda

Emergencias

Volumn 27, Issue 4, 2015, Pages 245-266

  Soriano, Pere Llorens ^a   Lorite, Nicolás Manito ^b   Espinosa, Luis Manzano ^c   Martín Sánchez, Francisco Javier ^a   Colet, Josep Comín ^b   Formiga, Francesc ^c   Jacob, Javier ^a   Jiménez, Juan Delgado ^b   Montero Pérez Barquero, Manuel ^c   Herrero, Pablo ^a   De Sá Areses, Esteban López ^b   Calvo, Juan Ignacio Pérez ^c   Masip, Josep ^b   Miró, Òscar ^a  

^a Grupo de Investigación en Insuficiencia Cardiaca Aguda de la Sociedad Española de Medicina de Urgencias y Emergencia   (Spain)

^b Sociedad Española de Cardiología   (Spain)

^c Sociedad Española de Medicina preventiva   (Spain)

Author keywords

Acute heart failure; Emergency health services; Integrated care

Indexed keywords

EID: 84937845470     PISSN: 11376821     EISSN: 23865857     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
3. Levitan EB, Wolk A, Mittleman MA. Consistency with the DASH diet and incidence of heart failure. Arch Intern Med. 2009;169:851-7.
4. Allender S, Scarborough P, O’Flaherty M, Capewell S. Patterns of coronary heart disease mortality over the 20th century in England and Wales: Possible plateaus in the rate of decline. BMC Public Health. 2008;8:148.
5. Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E, Jiménez Navarro M, Alonso-Pulpón L, Muniz García J, et al. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study. Rev Esp Cardiol. 2008;61:1041-9.
6. Rodríguez-Artalejo F, Banegas Banegas JR, Guallar-Castillón P. Epidemiology of heart failure. Rev Esp Cardiol. 2004;57:163-70.
7. Writing Group M, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
8. Neumann T, Biermann J, Erbel R, Neumann A, Wasem J, Ertl G, et al. Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Deutsches Arzteblatt international. 2009;106:269-75.
9. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3:283-91.
10. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361-71.
11. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12:1076-84.
12. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011;306:1669-78.
13. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101:1016-22.
14. Oxford Center for Evidence Based Medicine. (Consultado 6 Junio 2014). Disponible en: http://www.cebm.net/index.aspx?o=5653.
15. Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation. 2010;122:1975-96.
16. Singer AJ, Skopicki H, Thode HC, Peacock WF. Hemodynamic profiles of ED patients with acute decompensated heart failure and their association with treatment. Am J Emerg Med. 2014;32:302-5.
17. Mebazaa A, Gheorghiade M, Pina IL, Harjola VP, Hollenberg SM, Follath F, et al. Practical recommendations for prehospital and early inhospital management of patients presenting with acute heart failure syndromes. Critical Care Med. 2008;36(Suppl 1):S129-39.
18. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Hart Fail. 2012;14:803-69.
19. Llorens P, Miró O, Martín Sánchez FJ, Herrero Puente P, Jacob Rodríguez J, Gil V, et al. Guidelines for emergency management of acute heart failure: consensus of the Acute Heart Failure Working Group of the Spanish Society of Emergency Medicine (AHF-SEMES) in 2011. Emergencias. 2011;23:119-39.
20. Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, Heizer GM, et al. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail. 2013;15:456-64.
21. Harinstein ME, Flaherty JD, Fonarow GC, Mehra MR, Lang RM, Kim RJ, et al. Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart. 2011;97:1607-18.
22. Jacob J, Llorens P, Martín-Sánchez FJ, Herrero P, Álvarez A, Pérez-Durá MJ, et al. Prognostic value of emergency department testing for N-terminal fragment of brain natriuretic peptide in patients with acute heart failure: the PICASU-1 study. Emergencias. 2011;23:183-92.
23. Miró O, Jacob J, Martín-Sánchez FJ, Herrero P, Pavón J, Pérez-Durá MJ, et al. Prognostic implications of emergency department determination of B-type natriuretic peptide in patients with acute heart failure: the PICASU- 2 study. Emergencias. 2011;23:437-46.
24. Comín-Colet J, Enjuanes C, González, Torrens A, Cladellas M, Meron O. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15:1164-72.
25. Nijst P, Mullens W. The Acute Cardiorenal Syndrome: Burden and Mechanisms of Disease. Curr Heart Fail Rep. 2014;11:453-62.
26. Llorens P, Miró Ò, Herrero P, Martín-Sánchez FJ, Jacob J, Valero A, et al. Clinical effects and safety of different strategies for administering intravenous diuretics in acutely decompensated heart failure: a randomised clinical trial. Emerg Med J. 2014;31:706-13.
27. Mentz RJ, Felker GM, Ahmad T, Peacock WF, Pitt B, Fiuzat M, et al. Learning from recent trials and shaping the future of acute heart failure trials. Am Heart J. 2013;166:629-35.
28. Emerman CL. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department. Rev Cardiovasc Ned. 2003;4(Suppl 7):S13-20.
29. Peacock WF, Emerman CL. Emergency department management of patients with acute decompensated heart failure. Heart Fail Rev. 2004;9:187-93.
30. Collins SP, Lindsell CJ, Storrow AB, Fermann GJ, Levy PD, Pang PS, et al. Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy. Heart Fail Rev. 2012;17:387-94.
31. Jacob J, Martín-Sánchez FJ, Herrero P, Miró Ò, Llorens P, miembros del grupo ICA-SEMES. Prognostic value of troponin in patients with acute heart failure attended in Spanish Emergency Departments: TROPICA study (TROPonin in acute heart failure). Med Clin (Barc). 2013;140:145-51.
32. Gheorghiade M, Vaduganathan M, Ambrosy A, Bohm M, Campia U, Cleland JG, et al. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev. 2013;18:107-22.
33. Cleland JG, Chiswell K, Teerlink JR, Stevens S, Fiuzat M, Givertz MM, et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo- Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circ Heart Fail. 2014;7:76-87.
34. Lee DS, Stitt A, Austin PC, Stukel TA, Schull MJ, Chong A, et al. Prediction of heart failure mortality in emergent care: a cohort study. Ann Intern Med. 2012;156:767-75.
35. Stiell IG, Clement CM, Brison RJ, Rowe BH, Borgundvaag B, Aaron SD, et al. A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events. Acad Emerg Med. 2013;20:17-26.
36. Cotter G, Metra M, Davison BA, Senger S, Bourge RC, Cleland JG et al. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. Eur J Heart Fail. 2014;16:1362-71.
37. Cohen-Solal A, Laribi S, Ishihara S, Vergaro G, Baudet M, Logeart D, et al. Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores. Arch Cardiovasc Dis. 2015;108:64-74.
38. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779-89.
39. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al.; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883-91.
40. Ertl G, Nitschmann S. Therapy of chronic heart failure--carvedilol vs. metoprolol. COMET Study. Der Internist. 2004;45:835-6.
41. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625-33.
42. Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, et al. Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J. 2000;139:15-22.
43. Metra M, Torp-Pedersen C, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail. 2007;9:901-9.
44. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008;52:190-9.
45. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
46. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12:423-33.
47. Peacock WF, Young J, Collins S, Diercks D, Emerman C. Heart failure observation units: optimizing care. Ann Emerg Med. 2006;47:22-33.
48. Collins SP, Pang PS, Fonarow GC, Yancy CW, Bonow RO, Gheorghiade M. Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol. 2013;61:121-6.
49. Peacock WF, Fonarow GC, Ander DS, Maisel A, Hollander JE, Januzi JL, et al. Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. Crit Pathw Cardiol. 2008;7:83-6.
50. Comín-Colet J, Verdú-Rotellar JM, Vela E, Clèries M, Bustins M, Mendoza L, et al. Efficacy of an Integrated Hospital-primary Care Program for Heart Failure: A Population-based Analysis of 56 742 Patients. Rev Esp Cardiol. 2014;67:283-93.
51. Kidwell C, Lyden P, Lewis B, Morgenstern LB, Qureshi AI, Brass R, et al. Guidelines for the Early Management of Adults With Ischemic Stroke. A scientific statement from the Stroke Council of the American Heart/American Stroke Association. Stroke. 2007;38:1655-711.
52. García-Moll X. Luces y (algunas) sombras en el manejo del síndrome coronario agudo en España: el estudio DIOCLES. Rev Esp Cardiol. 2015;68:85-6.
53. Masip J. Ventilación mecánica no invasiva en el edema agudo de pulmón. Rev Esp Cardiol. 2001;54:1023-8.
54. Masip J, Roque M, Sánchez B, Fernández R, Subirana M, Expósito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA. 2005;294:3124-30.
55. Weng CL, Zhao YT, Liu QH, Fu CJ, Sun F, Ma YL, et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med. 2010;152:590-600.
56. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359:142-51.
57. Thomson MR, Nappi JM, Dunn SP, Hollis IB, Rodgers JE, Van Bakel AB. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Cardiac Fail. 2010;16:188-93.
58. Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013;5:227-45.
59. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378:667-75.
60. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebocontrolled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378:676-83.
61. Albaghdadi M, Gheorghiade M, Pitt B. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J. 2011;32:2626-33.
62. Ferrario CM, Schiffrin EL. Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. Circ Res. 2015;116:206-213.
63. Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, et al. Decongestion in acute heart failure. Eur J Heart Fail. 2014;16:471-82.
64. George M, Rajaram M, Shanmugam E, VijayaKumar TM. Novel drug targets in clinical development for heart failure. Eur J Clin Pharmacol. 2014;70:765-74.